Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06374849
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-16
Brief Title:
Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery
Sponsor:
Centre Hospitalier Universitaire Amiens
Organization:
Centre Hospitalier Universitaire Amiens
Study Overview
Official Title:
Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ISPAIN
Brief Summary:
Several risk factors for chronic postoperative pain have been identified A series of studies have shown that administrating intraoperatively a high dose of Remifentanil is associated with an increased incidence of CPSP These findings highlight a risk factor for CPSP that the anaesthetist can influence on but they however remain limited to remifentanil To this day no study have attempted to evaluate the existence of such an association between the incidence of CPSP and the intraoperative administration of sufentanil doses Improved knowledge of the long-term nociceptive impact of intraoperative sufentanil administration would enable better therapeutic adaptation according to each patients risk
In the field of CPSP non-major abdominal surgeries remain poorly studied This is due to their lower risk of CPSP than other surgeries such as orthopaedic mammary or thoracic surgery Nevertheless they constitute a large number of daily surgical procedures The estimated incidence of CPSP in non-major abdominal surgery appears in several studies to be between 15 and 20 The aim of this study is to evaluate the correlation between the intraoperative administration of sufentanil doses and the incidence of CPSP at 3 months in patients undergoing non-major scheduled abdominal surgery
In the field of CPSP non-major abdominal surgeries remain poorly studied This is due to their lower risk of CPSP than other surgeries such as orthopaedic mammary or thoracic surgery Nevertheless they constitute a large number of daily surgical procedures The estimated incidence of CPSP in non-major abdominal surgery appears in several studies to be between 15 and 20 The aim of this study is to evaluate the correlation between the intraoperative administration of sufentanil doses and the incidence of CPSP at 3 months in patients undergoing non-major scheduled abdominal surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None